top of page
Browse by category
Search
GLP-1RAs may lead to increased risk of aspiration pneumonia following endoscopy
People who are scheduled for certain medical procedures should stop taking glucagon-like peptide-1 receptor agonists (GLP-1RAs)...
Medications for type 2 diabetes and weight loss poorly prescribed
Three independent, preliminary research studies have found that new type 2 diabetes and weight-loss medications are often not prescribed...
GLP-1s do not increase aspiration or pneumonia in surgery patients
There is no association between prescription glucagon-like peptide-1 (GLP-1) agonist medications and increased risk of aspiration or...
GLP1 agonists associated with a reduced risk of developing cirrhosis and liver cancer in people with T2DM and chronic liver disease
Glucagon-like peptide-1 receptor (GLP1) agonists are associated with a reduced risk of developing cirrhosis and liver cancer in people...
Mazdutide demonstrates significant weight loss efficacy and multiple metabolic benefits
The 48-week outcomes from a Phase 2 clinical study of higher dose (9mg) mazdutide in Chinese subjects with obesity have demonstrated...
Low adherence and increased cost in first year of taking GLP-1a drugs for weight loss
An analysis of real-world integrated pharmacy and medical claims data by leading pharmacy benefit manager Prime Therapeutics and Magellan...
ASA’s Task Force: Stop taking GLP-1 medications for diabetes and weight loss before elective surgery
With the growing popularity of medications like Ozempic (semaglutide), Trulicity (dulaglutide) and other glucagon-like peptide-1 (GLP-1)...
Journal Watch 11/05/2023
Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. as ever, we have...
GLP-1 analogues can actually restore anticancer NK immune cells
Researchers from the Londsdale Health Institute at Maynooth University, have found that glucagon-like peptide (GLP-1) analogues, can...
Browse by tag
bottom of page